Global Chronic Idiopathic Constipation Drugs Market:Industry Growth, Analysis, and Forecast To 2022 – by Credence Research
The latest market report published by Credence Research,
Inc. “Global Chronic Idiopathic Constipation (CIC) Drugs Market -
Growth, Share, Opportunities, Competitive Analysis, and Forecast,
2016-2022,” the chronic idiopathic constipation drugs market was
valued at USD 1675.4 Mn in 2015, and is expected to reach USD 2570.8 Mn by
2022, expanding at a CAGR of 6.4% from 2016 to 2022.
Browse the full report Chronic
Idiopathic Constipation (CIC) Drugs Market - Growth, Share, Opportunities,
Competitive Analysis, and Forecast, 2016–2022 at http://www.credenceresearch.com/report/chronic-idiopathic-constipation-cic-drugs-market
Market Insights
Growing awareness and increasing
incidence and prevalence of chronic idiopathic constipation – CIC are the major
factors driving the CIC drugs market worldwide. Growth in demand for CIC drugs
in Asia Pacific, coupled with the huge gap of unmet needs in the region is
expected to serve as a significant opportunity in the global market during
forecast period.
In terms of geographical
distribution, North America captures over 40% share of the global market
revenue. US is the largest national market for CIC drugs due to greater
prevalence of lifestyle respective diseases, higher incidence of constipation,
higher healthcare spending and rather greater adoption of pharmaceuticals for
treating ailments. As per the National Institutes of Health (NIH) CIC affects
approximately 63 Mn individuals in the US. On the other hand, growing awareness
in the rapidly developing Asian countries such as China and India will create
significant growth opportunities in the Asia Pacific market.
In terms of market segmentation by
drug type, Lubiprostone drugs segment currently dominates the market. However,
the segment due to its relatively lower efficacy, patent loss and growing
competition from Linaclotide will lose its dominance in the upcoming future.
The Linaclotide drugs market for CIC treatment is anticipated to grow at a CAGR
of 7.7% during 2016 – 2022.
Analyzing the symptoms, constipation
is not considered as a disease but a condition, side effect or syndrome. This
factor greatly contributes to the lesser visits from patients to address the
issue. Thus over 65% of the CIC drugs market is captured by OTC drugs segment.
The OTC market is expected to continue to dominate the market at a CAGR of 6.6%
during 2016 – 2022.
The CIC drugs market is
currently open for further research and development and thus introduction of
novel pharmaceutical solutions. Actavis, Chugai Pharmaceutical, Ferrin
International, Synergy Pharmaceuticals and others are among the top payers
active in the global chronic idiopathic constipation drugs market.
About Us:
Credence Research is a worldwide market research and
counseling firm that serves driving organizations, governments, non-legislative
associations, and not-for-benefits. We offer our customers some assistance with
making enduring enhancements to their execution and understand their most
imperative objectives. Over almost a century, we’ve manufactured a firm
extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more
than 15 research consultants and almost 100 research and information
professionals.
Our customers mirror our worldwide nature. Around 45% are
in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East
and Africa.
Our firm is intended to work as one. We are a solitary
global research organization united by a solid arrangement of qualities,
concentrated on customer effect.
What we do
We serve customers at each level of their organization, in
whatever limit we can be most helpful, whether as a trusted counsel to top
management or as a hands-on mentor for forefront representatives. For each
engagement, we collect a group with the most suitable experience and ability.
No matter the challenge, we concentrate on delivering
functional and persevering results, and preparing our customers to develop and
lead. We join forces with customers to place suggestions into practice. Our
research specialist work straightforwardly with customers over long stretches
to create workforce aptitudes, drive operational change, and apply new working
strategies.
Contact:
Name: Chris Smith
Designation: Global Sales Manager
Ph: +1-800-361-8290
Post a Comment